Tom G. Jacobs

Hilversum, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.

Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.

Journal: The lancet. HIV

Published: March 23, 2026

Comparative evaluation of handwriting recognition by large language models (LLMs) in interpreting handwritten medication lists.

Comparative evaluation of handwriting recognition by large language models (LLMs) in interpreting handwritten medication lists.

Journal: Exploratory research in clinical and social pharmacy

Published: March 17, 2026

Interpreting ganciclovir plasma concentrations to inform dosing and therapeutic drug monitoring in (preterm) infants with CMV.

Interpreting ganciclovir plasma concentrations to inform dosing and therapeutic drug monitoring in (preterm) infants with CMV.

Journal: The Journal of infectious diseases

Published: March 03, 2026

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment.

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment.

Journal: The Journal of antimicrobial chemotherapy

Published: February 19, 2026

Evaluation of drug-drug interactions associated with metamizole in clinical practice.

Evaluation of drug-drug interactions associated with metamizole in clinical practice.

Journal: Expert review of clinical pharmacology

Published: February 10, 2026

Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial.

Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial.

Journal: EClinicalMedicine

Published: January 08, 2026

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial.

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial.

Journal: Lancet (London, England)

Published: December 11, 2025

Sustainable use of IV bags: lessons from the IV bag crisis

Sustainable use of IV bags: lessons from the IV bag crisis

Journal: Nederlands tijdschrift voor geneeskunde

Published: November 19, 2025

Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.

Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.

Journal: Antiviral research

Published: September 03, 2025

Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs.

Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs.

Journal: Expert opinion on drug metabolism & toxicology

Published: August 08, 2025

Commentary: Pediatric HIV Treatment: Nurturing Access Through Health Facility Availability and Stock-out Monitoring.

Commentary: Pediatric HIV Treatment: Nurturing Access Through Health Facility Availability and Stock-out Monitoring.

Journal: The Pediatric infectious disease journal

Published: April 10, 2025

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Journal: EBioMedicine

Published: April 02, 2025

Showing 1-12 of 52

Last Updated: 09/26/2026